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Breast cancer is a disease that can affect all women. However, the rate at which this disease 
affects women varies by race and ethnicity.  
When one analyzes incidence rates for a life threatening disease, a higher incidence rate 
for a certain group usually portends a higher death rate.  However this is not necessarily true for 
breast cancer. In particular, when comparing incidence rates with their white counterparts, 
African American women have a lower incidence rate but a higher death rate.   
The phenomenon of racial differences or health disparities among cancer patients has 
been established several times by studies primarily associated with differences in health care in 
the general population.  However, within randomized clinical trials, one does not anticipate that 
disparities in health outcome would be evident as all patients receive treatment in accordance 
with standard treatment protocols.  The purpose of this study is to test this premise by  asking the 
question: Is there a difference in radiation treatment when comparing African American and 
Caucasian women who are treated in randomized clinical trials?   
The study population includes patients from the National Surgical Adjuvant Breast and 
Bowel Project (NSABP) on various protocols (B15, B16, B18, B22, B23, B25, and B28). The 
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focus was on patients who received chemotherapy in the form of Adriamycin and 
cyclophosphamide (AC), alone or prior to other chemotherapy agents.  AC was given as adjuvant 
in all of the protocols.  There were 9,646 Caucasian patients and 1,040 African-American (AA) 
patients.  Among these patients were 3,504 Caucasian patients and 377 AA patients who 
received radiation therapy according to protocol. 
After adjusting for various potential confounders no evidence was found of a difference 
by race in total radiation therapy. 
Public health importance:  Randomized clinical trials provide important evidence for the 
choices of breast cancer treatment.  The success of such trials in providing an environment where 
patients received a standardized treatment would be called into question if there were treatment 
differences by race in those trials. This study did not find evidence of racial disparity in radiation 
therapy in the NSABP breast cancer trials examined. 
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1.0  INTRODUCTION 
1.1 WHAT IS BREAST CANCER? 
Although breast cancer is a disease that can affect all women, the rate at which this disease 
affects women varies by race and ethnicity.i
Cancer occurs when a malignant tumor, an abnormal and uncontrollable growth, 
develops in the body tissue. Cancers are named based for the body tissue of origin. Thus, cancers 
that form in the breast tissue are labeled as breast cancer.   
  According to the Center for Disease Control (CDC) 
in 2005, 186,467 women developed breast cancer and 41,116 died from the disease in the United 
States (CDC 2009).   
Malignant, or cancerous, breast tumors are capable of spreading to parts of the body 
beyond the breast (NCI 2009).   Benign breast tumors are not life threatening and do not spread 
outside the breast (NCI 2009). 
The cells in breast tissue may cycle between states of proliferation and quiescence.    
Uncontrolled cell growth does not occur when gene function is in equilibrium.   When this 
balance is lost, uncontrolled and aberrant cell growth results.  Along with abnormal growth, 
cancerous tumors can spread through lymphatic and vascular pathways to involve lymph nodes 
and other tissues in the body.  This process is referred to as metastasis (NCI 2009).     
 2 
Lymph nodes are small glands or organs that are connected by lymphatic vessels.  Breast 
cancer cells can enter the small, vein-like lymphatic vessels and begin to grow (ACS 2009).  
When lymph nodes are affected by breast cancer they are labeled as “positive” and when the 
lymph nodes are not affected they are labeled as “negative”.  The number of lymph nodes 
positive or negative is very important in determining the appropriate treatment.  Doctors usually 
characterize a patient’s stage and prognosis, in part, based upon the number of either clinically or 
pathologically positive lymph nodes (NCI 2009). 
Figure 1 is an image of normal breast cells.  Each breast has several sections called lobes 
and each lobe has smaller sections called lobules (B). The cancer usually forms in the breast 
ducts that carry milk to the nipple, (D), and the lobules, (B), that make the milk (natural-disease-
solutions.com 2009).   The rest of the breast consists predominately of adipose tissue. 
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Figure 1. Normal Breast Tissue 
Adapted from natural-disease-solutions.com 01/08/2009 
Bill Montgomery 
Breast profile: 
A Ducts 
B Lobules 
C Dilated section of duct to hold milk 
D Nipple 
E Fat 
F Pectoralis major muscle 
G Chest wall/rib cage 
Inset 
A Normal duct cells 
B Basement membrane 
C Lumen (center of duct) 
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Breast cancer is made up of two main types, noninvasive and invasive and is usually 
classified by the kind of tissue in which the cancer starts and by the extent of its spread.  
Noninvasive breast cancer can be classified as ductal carcinoma in situ (DCIS), Figure 2, and 
lobular carcinoma in situ (LCIS) (NCI 2007).  In DCIS, abnormal cells originate in the ducts and 
are confined to the milk ducts of the breast, accounting for 20 to 30 % of breast cancers.  With 
LCIS, abnormal cells originate in the lobules and proliferate within milk-producing glands of the 
breast.  Women with LCIS have a 30% chance of developing invasive breast cancer in the same 
or opposite breast during the subsequent 2-3 decades following the original diagnosis 
(Merck.com 2009).  LCIS accounts for 1 to 2 percent of breast cancer. With both of these 
classifications, there are abnormal cells present but they have not invaded surrounding tissue.  
Even though the cells in the breast are not cancerous with carcinoma in situ, this is an indication 
that breast cancer may develop at a later time (Breastcancer.org 2009).  
Figure 3 is an image of invasive breast cancer.  
Breast cancer that begins in the ducts and spreads to nearby tissue is called invasive 
ductal carcinoma (IDC), which accounts for about 65 to 80 percent of all breast cancers 
(Merck.com 2009). IDC originates in the milk ducts invading the surrounding breast tissue by 
breaking through the wall of the ducts.  Breast cancer that begins in the lobes and spreads to 
nearby tissue is called invasive lobular carcinoma (ILC) (BreastCancer.org 2009).    ILC begins 
in the part of the breast that produces milk and spreads to other parts of the body by invading the 
surrounding breast tissue.  This type of invasive breast cancer accounts for 10 to 15 percent of 
breast cancers (Merck.com 2009).  Inflammatory breast cancer (IBC) is an uncommon type of 
invasive cancer that is fast-growing and often fatal.  The cancer cells block the lymphatic vessels 
in the skin of the breast, causing the breast to appear inflamed, look swollen and red, and even 
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feel warm.  This type of breast cancer usually spreads to the lymph nodes of the armpit.  These 
axillary lymph nodes can feel like hard lumps but often no individual, discrete lump is felt in the 
breast because this cancer is dispersed throughout the entire breast itself.  Inflammatory breast 
cancer accounts for about 1% of breast cancers (Merck.com 2009). 
 
Figure 2. Ductal Carcinoma in situ (DCIS) 
Adapted from NCI 01/08/2009 
Don Bliss (artist) 
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Figure 3. Invasive Breast Cancer 
Adapted from NCI 01/08/2009 
Don Bliss (artist) 
 
 
 
 
1.2 INCIDENCE AND MORTALITY 
When one analyzes incidence rates for a life threatening disease, a higher incidence rate for 
certain groups usually portends a higher death rate.  However, this is not necessarily true for 
breast cancer. 
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In the United States, breast cancer mortality rates are increasing and there are significant 
survival differences for African-American women (Jotoi 2005, Shiao 1997).  African-American 
women have lower incidence rates of breast cancer, but, compared to white women, they are 
known to have a higher breast cancer mortality rates (Jotoi 2005). 
When comparing breast cancer incidence and mortality rates, African Americans have a 
higher incidence but a lower mortality rate. The incidence and mortality rates are 117.5 and 33.5 
(per 100,000) for African American woman, 130.6 and 24.4 (per 100,000) for white women 
(Jemal 2009).  This leads to African American women, for breast cancer alone, having an 11% 
lower incidence rate and a 37% higher death rate.1
 During the years 1992 to 1998, white women had a higher incidence rate compared not 
only to black women also to other races as well.  Death rates among African American women 
increased between the years of 1975 and 1991 annually and then declined in women 50 years of 
age or younger after 1991 (ACS 2009). 
  
1.3 DIAGNOSIS AND PROGNOSIS 
1.3.1 Treatment  
After a woman is diagnosed with breast cancer, staging of the tumor is carried out to determine 
the disease extent and formulate an appropriate treatment plan.  However, treatment algorithms 
may be complex because the different types of breast cancer differ greatly in growth rate, 
                                                 
1 Per 100,000 population, age adjusted to the 2000 US standard population  
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tendency to spread, and response to treatment.  In addition, individual practitioners may have 
different opinions about the most appropriate treatment for women with the same type of breast 
cancer.  Treatment usually involves surgery and may include cytotoxic chemotherapy, radiation 
therapy, hormonal   therapy, and/or novel targeted antiproliferative systemic therapy.  Often, a 
combination of these treatments is used (NCI 2009).  The different stages of breast cancer are 
localized non-invasive, localized invasive, regional invasive and distant invasive.  The different 
stages can also be labeled using numbers I-IV, respectively.  If the cancer has not progressed to 
stage I or higher, carcinoma in situ, stage 0 is a precancerous condition and surgery is the method 
used at this stage.   If the cancer has progressed to stage higher then or I there are five types of 
treatment used: surgery, chemotherapy, hormone therapy, radiation therapy, and/or novel 
targeted antiproliferative systemic therapy (NCI 2009).  These modalities are usually 
administered sequentially.  
Surgical extirpation is the mainstay of treatment approaches for both invasive and non-
invasive local and/or regional breast cancer. Surgery is used to remove the cancer from the breast 
as well as from the axillary lymph nodes.  The lymph nodes are then examined for the presence 
of cancerous cells.  There are several types of surgical procedures that can be performed 
depending upon the stage, including but not limited to lumpectomy, quadrectomy partial 
mastectomy, total mastectomy, modified radical mastectomy, and radical mastectomy (NCI 
2009). A lumpectomy is a procedure that removes the tumor and a small amount of normal tissue 
around it.  A partial mastectomy, or segmental mastectomy, removes part of the breast that 
contains cancer and some normal tissue around it as well.  A total mastectomy is a procedure that 
removes the entire breast.  A modified radical mastectomy is a procedure that not only removes 
the whole breast, but also axillary lymph nodes, the lining over the chest muscles and, from some 
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part of the chest wall muscles.  A radical mastectomy is the last surgical procedure that removes 
the breast containing cancer, the chest wall muscles under the breast, and all of the lymph nodes 
under the arm (NCI 2009). 
The second type of treatment discussed is cytotoxic chemotherapy.  Chemotherapy is the 
use of medications to stop the growth of the cancerous cells by killing cancerous cells, usually by 
inducing abnormal cell division.  Chemotherapy is administered orally or by injection into a vein 
or muscle.  Some of the drugs given during chemotherapy are doxorubicin (also referred to as 
Adriamycin), cyclophosphamide, methotrexate, fluorouracil, and taxanes (NCI 2009).  
The third type of treatment discussed is hormone therapy.  Estrogen is a hormone that is 
produced by a woman’s ovaries until menopause.  After menopause, small amounts of estrogen 
are still made and may promote the growth of breast cancer cells.  Signals are sent through 
receptors from estrogen telling estrogen-sensitive breast cancer cells to grow (ACS 2009).  
A test is usually given, known as an estrogen receptor assay, to determine if the cancer 
cells have hormone receptors.  After the test is administered, if breast cancer cells are found 
without receptors they are then labeled as estrogen-receptor negative or ER negative.  If the 
cancer cells are found with receptors they are labeled as estrogen-receptor positive or ER 
positive.  If estrogen receptors are present, hormone therapy is a usually a very good option 
(Breastcancer.org ACS 2009). These agents change the tumor microenvironment.  Tamoxifen is 
an anti-estrogen drug given to patients with early stages of breast cancer and metastatic breast 
cancer.  Tamoxifen is usually given for up to five years but can be taken for longer periods of 
time (Breastcancer.org 2009).  Aromatase inhibitors, such as anastrazole, are given to stop the 
production of estrogen.  They work by blocking the enzyme, aromatase, responsible for making 
estrogen in postmenopausal women (ACS 2009). 
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The fourth type of treatment discussed is targeted therapy at the human epidermal growth 
factor receptor 2 (HER2). HER2 is a gene that produces HER2 protein. It is found in normal 
breast cells and aids in their growth. In the presence of abnormally high amounts of HER2 genes, 
an “over expression” of the protein occurs. This “over expression” allows cancer cells to 
proliferate and divide more quickly. Cancer cells with this “over expression” are labeled as 
HER2 positive (HER2+) (Breastcancer.org 2009). 
The last type of treatment to discuss is radiation therapy and its utilization is dependent 
on the type and stage of cancer.  The two types of ionizing radiation therapy, external and 
internal, use high-energy x-rays (photons) or electrons.  External beam radiation uses a machine 
known as a linac, an abbreviation for linear accelerator, to direct radiation toward the cancer.  
Internal radiation also known as brachytherapy uses a radioactive substance such as iridium-192 
or iodine-125, sealed in needles, seeds, wires, or a catheter placed directly into or near the cancer 
(ACS 2009).  Radiation therapy, which causes double-stranded DNA, breaks, preferentially in 
cancer cells that in G2/M phase of the cell cycle may take takes days or weeks to kill all the 
cancer cells.  Radiation therapy is often administered in conjunction with other cancer treatments 
such as surgery and chemotherapy.  Radiation can be given before, during, or after surgery or 
chemotherapy.  If given before surgery it is used to shrink the size of the cancer.  If given during 
surgery it is used so that it goes straight to the cancer without passing through the skin.  If it is 
given after surgery, it is used to kill any cells that may remain.  Also, chemotherapy can be given 
so that radiation therapy is more efficient.  Radiation therapy is often administered after women 
have had a lumpectomy (NCI 2009).  This paper will focus on radiation therapy. 
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1.4  STUDIES OF TREATMENT DIFFERENCES AND DIFFERENCES IN INCIDENCE 
AND MORTALITY RATES WHEN COMPARING AFRICAN AMERICAN AND WHITE 
WOMEN IN THE GENERAL POPULATION. 
The National Institutes of Health (NIH) developed a definition of cancer health disparities: 
“Cancer health disparities are differences in the incidence, prevalence, mortality, and burden of 
diseases and other adverse health conditions that exist among specific population groups in the 
United States.” (NIH 2009)  An  example of a health disparity is noted in a retrospective, 
longitudinal cohort study among newly diagnosed breast cancer patients covered by the same 
health plan in south-eastern US (Short et al 2009).  The cohort included patients from an 
administrative medical claims database between the years 1/2000 to 12/2004.  The study found 
that African American women, at diagnosis, were significantly younger (p=.001) and had twice 
the rate of hypertension (p=<.001) when compared to white women (Short 2009).  The analyses, 
after adjusting for age, geography according to RUCA, and SED, also  showed that African 
American women were at an increased odds for being diagnosed with a later stage of cancer 
(OR=1.71; 95% CI, 1.09-2.67; p=0.02) (Short 2009). 
Some factors that may contribute to the survival difference between African American 
and white women include lower quality of health care when accessible, a higher prevalence of 
coexisting conditions, and differences in tumor biology (Merck 2009).  In addition, African 
American women are often diagnosed with more advanced stages of the disease than white 
women.  Other proposed explanations that could account for this disparity include differences in 
treatment based on race, socioeconomic status (SES), sociocultural differences, unequal access to 
or provision of medical care, environmental factors, genetic factors and possibly biological 
factors (Hershman 2003).  
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According to Vona-Davis (2009) the average annual breast cancer mortality rate was 35.6 
per 100,000 and 28.2 per 100,000 for African American women and white women, respectively. 
Even though the death rate has decreased during the years 1990 to 2000, the rate of mortality has 
only decreased 1.0% for African American women and 2.5% for white women per year (Vona-
Davis 2009) 
The phenomenon of racial difference or health disparity among cancer patients has been 
established in several studies.  One proposed reason for this phenomenon is the low rate of 
screening, contributing to the late stage of diagnosis.  In the study by Morris et al (2004) blacks, 
compared to whites, were diagnosed with breast cancer at a much younger age and at a more 
severe stage (Morris 2004).  Another study by Li et al (2003) also found that in the US, black 
women have more advanced stages of breast cancer and have lower survival rates compared to 
non-Hispanic whites .   
An association was also found between early termination of chemotherapy and racial 
disparities in breast cancer outcomes (Hershman 2003). The white blood cell count (WBC), 
which differs among racial groups, can also play an important role when determining treatment 
and the amount of treatment a patient can withstand.  On average, African-American women 
have 25% - 40% lower WBC counts compared to European-American women (Hershman 2003).  
For patients undergoing adjuvant chemotherapy, if the WBC count falls below a predefined 
treatment threshold, a reduction in dose or treatment delay may occur (Hershman 2003).  Other 
options, such as treatment termination or change in dose, can also occur. 
The findings of Hershman and colleagues (Hershman 2003) support the conclusion of 
Mandelblatt et al (2005) in that it would be more cost-effective to make sure black women 
receive complete adjuvant therapy than to change or create a different screening program.  
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Ensuring completion could also reduce overall mortality (Hershman 2005). Hershman et al. 
found an overall statistically significant difference between African-American women and white 
women, with the length of treatment for newly diagnosed stage I and II breast cancer.  In their 
study, African American women were treated for 19 weeks and white women were treated for 15 
weeks, with a difference of 4 weeks (p=0.03).  African American women were able to have 
longer treatment because of lower dose intensity (Hershman 2003). Chu et al (2003) established 
that African American women, when compared to white women, have more advanced-stage 
breast cancer and less early stage breast cancer.  This in turn would give reason for African 
American women having lower survival rates. 
Racial differences in treatment and standard of care could also be other factors in lower 
survival rates.  For African American women and white women with the same disease stage and 
diagnosis, a randomized clinical trial was performed. The clinical trial showed that equal 
utilization of medical services leads to equal survival rates, while unequal survival rates based on 
the stage could indicate racial differences in treatment (Chu 2003). Other observations shown by 
Diehr et al (1989), observed a treatment difference when looking at radiation therapy in 
combination with radical/modified mastectomy.  Black women were less likely to receive the 
therapy and were less likely to receive rehabilitation services after enduring mastectomy. They 
were referred less often for post mastectomy rehabilitation and were less likely to have 
progesterone receptor assay when compared to white patients.  Blacks also significantly differed  
with respect to health insurance, hospital, and physician characteristics. Schneider et al (2002) 
found that black patients, relative to white patients, were less likely to be screened for breast 
cancer, (62.9% vs. 70.9%; p<.001) (Schnieder 2002). 
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The reason for giving cancer statistics for African Americans is to highlight areas where 
better prevention, early detection, and treatment can reduce their excessive affliction of suffering 
and death from breast cancer (Merck 2009). 
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2.0  RESEARCH QUESTION: IS THERE A DIFFERENCE IN THE DOSE, THE NUMBER 
OF DAYS OR INTENSITY OF RADIATION THERAPY BETWEEN AFRICAN AMERICAN 
AND CAUCASION WOMEN IN CLINICAL TRIALS? 
There is compelling evidence documenting the differences of diagnosis, treatment, and death 
rates between African-American women and Caucasian women treated in the general population.  
In the randomized clinical trial setting, it is the premise that because all patients are treated by 
the same high-quality treatment protocol, all patients get equivalent quality of care. Several 
articles exist discussing racial health disparities in the general population and the treatment 
option of chemotherapy. Radiation therapy however, did not have such an extensive  literature.   
As a result I wanted to further examine radiation treatment.  The NSABP is a known clinical trial 
coorperative group that has established different standards in breast cancer treatment.  The 
following question arises: Is there a difference in quality of radiation treatment between African 
American and Caucasian women in clinical trials? Quality of radiation treatment will be defined 
as dose (the amount of radiation therapy received), days (the number of radiation therapy days 
completed), and intensity (dose/days).  
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3.0  METHODS 
3.1 PATIENT/DATA SOURCE 
The study  samples were breast cancer patients enrolled in several randomized clinical trials 
performed by the National Surgical Adjuvant Breast and Bowel Project (NSABP).  Table 1 lists 
these protocols and identifies the treatments that were used in these trials.  Tables 2 and 3 list the 
numbers of patients by protocol  and race and the number of patients by type of treatment and  
race, respectively. 
For the purpose of this paper, not all arms of treatment will be used.  The focus will be on 
women who received chemotherapy in the form of Adriamycin and cyclophosphamide (AC), 
alone or prior to other chemotherapy agents.  There were 9,646 Caucasian women and 1,040 
African American (AA) women. Women who qualified for radiation therapy according to the 
protocol were women who had lumpectomy surgery and completed 4 cycles of AC 
chemotherapy.  Forty women were also recommended for RT for reasons that were unknown, 
even though they had mastectomy surgery.  This information was not available.  These women 
were excluded from the final analysis because they did not follow the recommended RT 
protocol. Among these patients were 3,305 Caucasian women and 377 African American women 
receiving radiation therapy per protocol and were analyzed. 
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This paper will compare African American and Caucasian women with respect to total radiation 
received, duration of radiation treatment, and intensity of the radiation treatment. 
All analysis was done in SAS 9.2. 
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4.0  ANALYSIS 
4.1 LOGISTIC REGRESSION 
Logistic regression was used as the method of analysis.  The independent, or predictor variables 
that were assessed included race, age, number of positive nodes, the number of AC cycles 
completed (which ranged from 1 ), pathologic tumor size, and protocol.  The dependent, or 
outcome, variables that were used included three measures of radiation therapy: 1) dose (the total 
amount of radiation therapy administered); 2) days (the number of radiation therapy days 
completed); and 3) dose intensity (dose/days).  As race was the main focus of this analysis, the 
approach for each of the three outcome measures of radiation therapy was to first assess the 
association between race and outcome without adjustment for any potential confounder 
variables.  The second step was to construct a model that included all significant independent 
factors, and then add race to this model to test if there was a difference by race in radiation 
dosing.  This approach provided a control for any possible confounders.  The multivariate model 
was constructed using a forward stepwise process.  Chi-squared tests were used to assess each 
variable’s model inclusion with an alpha of 0.05 as the criterion for entry and removal. Once the 
multivariate model was identified, race was added and tested for statistical significance.   
Race, number of positive nodes, number of cycles of AC, and protocol were categorical 
variables, while age and tumor size were continuous variables.  Race was coded 0 for Caucasian 
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and 1 for African American.  Number of positive nodes was coded 0 for 0 positive nodes, 1 for 
1-3 positive nodes, 2 for 4-9 positive nodes, and 3 for 10+ positive nodes.  Cycle was coded 0 
for less than four cycles of AC and 1 for received all four cycles of AC.  Protocol was coded 15, 
16, 18, 22, 23, 25, and 28 corresponding to the cancer protocol.  The outcome variables for this 
analysis were originally continuous in nature (Figures 6-10); due to the non-normality of their 
distributions I chose to dichotomize the outcomes and use regression models for binary response 
data.  Binary response model were used where the response (days, dose, or intensity)  was a 
dichotomous variable that would equal 0 if the woman received less than the targeted radiation 
therapy and 1 if the woman receive greater than or equal to the targeted radiation therapy.    Days 
equaled 0 for less than 35 days of RT and 1 for greater than or equal to 35 days of RT.  Dose 
equaled 0 for less than 5,000 rads2
 The logistic model has the form    
 and 1 for greater than or equal to 5,000 rads.  Intensity 
equaled 0 for 142.86 rads/days and 1 for greater than or equal to 142.86 rads/days.  These 
numbers were chosen based on the targeted or recommended RT according to the protocol. 
 
  Where α is the intercept parameter and β is the vector of slope parameters.  The βs provide 
information about the relationships of the independent variables to the dependent variables.  The 
estimates of the population coefficients are 𝛼𝛼� and ?̂?𝛽.  Maximum likelihood estimation is used to 
make the estimates.  This technique of maximum likelihood finds the value of the parameter that 
is most likely to have produced the observed sample data.  P is the probability of a success, or in 
this analysis the probability of receiving the recommended amount radiation therapy. 
                                                 
2 The term “rads” that is used it similar to”centigray” or “cGy” 
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Odds ratios were obtained to quantify the relationship between the predictors and the 
outcomes.  An odds is the probability that some event will occur divided by the probability that 
the same event will not occur.  Odds (E) =  =   Here E is the probability that some 
event will occur and  is the probability that same even will not occur.  An odds ratio is the ratio 
of two odds.  When comparing two groups the Odds Ratio =  =  = 
.  Where a and b are two groups thus Ea is the probability that some event 
will occur in group a and Eb is the probability that some even will occur in group b.  An odds 
ratio that is not statistically different than one indicates that the odds are the same in both groups 
therefore concluding that the two groups do not differ.  An odds ratio that is greater than one 
indicates that the odds of the event occurring in group A is greater than the odds of the event 
occurring in group B.  
 21 
5.0  RESULTS 
African American and Caucasian women were analyzed to see if there was a difference in the 
number of days of radiation therapy completed, the target radiation dose, and the treatment 
intensity.   
Tables 2 and 3 describe the number of African American and Caucasian women were in 
each protocol and treatment respectively. 
Completeness was defined as completing the recommended number of days according to 
the radiation protocol (35 days).  The majority of women completed all recommended days, 
327(86.7%) among AA patients and 3,101(88.3%) among Caucasian patients. Tables 4-10 are 
comparisons of patients and tumor characteristics.  
The 3 radiation doses (dose, days, and intensity) were originally continuous in nature; the 
data was highly concentrated around the mean compared to that of a normal distribution, due to 
lower variations within observations (Figures 6-11).  Due to the leptokurtic distributions I choose 
to dichotomize the doses.  Zero was given if a patient had less than the  recommended dose and a 
one if the patient received greater than or equal to the recommended dose. 
Several models were run to assess the completeness of radiation treatment when 
comparing African American and Caucasian women. Data were from the NSABP clinical trials 
conducted during the years of 1984 to 1998.  The majority of the women [404 AA women 
(38.9%) and 3,474 Caucasian (36.2%)] were between the ages of 40 and 49 (Table 4).  The 
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majority of women had between 1 to 3 positive nodes, [507 AA women (49.1%) and 5,211 
Caucasian women (54.4%)] (Table 5).  The most common range of tumor size was 1.0 - 2.0 cm 
for Caucasian women [2,263 women (32.7%)], whereas the most common tumor size was 
greater than or equal to 4.0 cm for African American women [232 women (31.5%)] (Table 
6).The majority of women completed all four cycles of AC [9,269 Caucasian women (96.4%) 
and 992 AA women (95.5%)] (Table 7).  The majority of the women completed the 
recommended dose [331 AA women (87.7%) and 3,183 Caucasian women (90.8%)] (Table 8), 
the recommended number of days [327 AA women (86.7%) and 3,101 Caucasian women 
(88.3%)] (Table 9), and therefore led to the majority of women receiving the appropriate 
intensity [296 AA women (78.5%) and 2,860 Caucasian women (81.4%)] (Table 10). 
 
 
 
Table 1. Protocols and Randomized Treatments in NSABP Protocols that Included African 
American Women 
 
NSABP Protocol 
Number                  Treatment Arms in the Protocol 
 
B-15 
 
AC vs. AC →CMF vs.  CMF 
  
B-16 TAM vs. ACT vs. PAFT 
  
B-18 POST-OP AC vs. PRE-OP AC 
  
B-22 AC vs. AC vs. AC 
  
B-23 CMF+Placebo vs. CMF+T vs. AC+Placebo vs. AC+T 
  
B-25 AC+G vs. AC+G vs. AC+G 
  
B-28 AC vs. AC->TX 
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Figure 4. Plot comparing the count of patients by number of days of radiation therapy completed for 
African American and Caucasian women 
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Figure 5. Plot comparing the percent of total days of radiation therapy completed for African 
American and Caucasian women 
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Figure 6. Plot comparing count of patients by the total dose of radiation therapy given for African 
American and Caucasian women 
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Figure 7. Plot comparing the percent of patients by total dose of radiation therapy given for African 
American and Caucasian women  
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Figure 8. Plot comparing the count of patients by dose intensity of radiation therapy for African 
American and Caucasian women  
 
 28 
0
10
20
30
40
50
60
70
80
Pe
rc
en
t
C
au
ca
sia
n
0 80 160 240 320 400 480 560 640 720 800 880 960 1040 1120 1200
0
10
20
30
40
50
60
70
80
Pe
rc
en
t
A
fri
ca
n-
A
m
er
ic
an
Dose/Days
 
Figure 9. Plot comparing the percent of patients by dose intensity for African American and 
Caucasian women 
 
Table 2.  Number of Patients by Protocol by and Race 
NSABP 
Protocol 
Number  
Caucasian 
African-
American Total 
N Pct N Pct N Pct 
B-15 1254 88.40% 164 11.50% 1418 100.00% 
B-16 351 93.60% 24 6.40% 375 100.00% 
B-18 (post-op) 573 88.00% 78 11.90% 651 100.00% 
B-22 1901 90.30% 204 9.60% 2105 100.00% 
B-23 739 84.00% 140 15.90% 879 100.00% 
B-25 2143 91.70% 192 8.20% 2335 100.00% 
B-28 2647 91.80% 236 8.10% 2883 100.00% 
Total 9608 90.20% 1038 9.70% 10646 100.00% 
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Table 3. Number of Patients by Type of Treatment and Race 
Type of 
Treatment  
Caucasian 
African-
American Total 
N Pct N Pct N Pct 
ACx4 626 88.20% 83 11.70% 709 100.00% 
ACx4 ->CMFx3 628 88.50% 81 11.40% 709 100.00% 
AC+TAM 351 93.60% 24 6.40% 375 100.00% 
AC+TAM if >=50 yrs 573 88.00% 78 11.90% 651 100.00% 
AC(C=600x4) 658 91.10% 64 8.80% 722 100.00% 
AC(C=1200x2) 616 89.40% 73 10.50% 689 100.00% 
AC(C=1200x4) 1342 91.30% 127 8.60% 1469 100.00% 
ACx4+TAM 1693 90.20% 183 9.70% 1876 100.00% 
ACx4+Placebo 369 83.60% 72 16.30% 441 100.00% 
AC(C=2400x2) 701 90.40% 74 9.50% 775 100.00% 
AC(C=2400x4) 727 92.60% 58 7.30% 785 100.00% 
ACx4->TAX+TAM 1324 91.60% 121 8.30% 1445 100.00% 
Total 9608 90.20% 1038 9.70% 10646 100.00% 
 
Table 4. Number of Patients by Age and Race 
Age  
(Years)  
Caucasian 
African-
American Total 
N Pct N Pct N Pct 
<30 156 1.60% 26 2.50% 182 1.70% 
30-39 1533 15.90% 227 21.80% 1760 16.50% 
40-49 3474 36.10% 404 38.90% 3878 36.40% 
50-59 2773 28.80% 261 25.10% 3034 28.40% 
60-69 1499 15.60% 103 9.90% 1602 15.00% 
>=70 173 1.80% 17 1.60% 190 1.70% 
Total 9608 100.00% 1038 100.00% 10646 100.00% 
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Table 5. Number of Patients by Number of Positive Nodes and Race 
Number of  
Positive 
Nodes 
Caucasian 
African-
American Total 
N Pct N Pct N Pct 
None 974 10.10% 160 15.50% 1134 10.60% 
1-3  5211 54.40% 507 49.10% 5718 53.90% 
4-9  2486 25.90% 271 26.20% 2757 25.90% 
10 902 9.40% 94 9.10% 996 9.30% 
Total 9573 100.00% 1032 100.00% 10605 100.00% 
 
Table 6. Number of Patients by Pathologic Tumor Size and Race 
Tumor Size 
(cm)  
Caucasian 
African-
American Total 
N Pct N Pct N Pct 
<1.0 322 4.60% 16 2.10% 338 4.40% 
1.0<-2.0 2262 32.70% 201 27.30% 2463 32.10% 
2.0<-3.0 1814 26.20% 187 25.40% 2001 26.10% 
3.0<-4.0 765 11.00% 100 13.50% 865 11.30% 
>=4.0 1753 25.30% 232 31.50% 1985 25.90% 
Total 6916 100.00% 736 100.00% 7652 100.00% 
 
Table 7. Number of Patients by Last Cycle of Radiation Therapy Completed and Race 
Last Cycle 
Of Radiation 
Completed  
Caucasian 
African-
American Total 
N Pct N Pct N Pct 
Cycle 1 83 8% 12 1.10% 95 8% 
Cycle 2 94 9% 11 1.00% 105 9% 
Cycle 3 163 1.60% 23 2.20% 186 1.70% 
Cycle 4 9268 96.40% 992 95.50% 10260 96.30% 
Total 9608 100.00% 1038 100.00% 10646 100.00% 
 
Table 8. Number of Patients by Radiation Dose and Race 
Radiation 
Dose (rads) 
Caucasian 
African-
American Total 
N Pct N Pct N Pct 
< 5000 322 9.10% 46 12.20% 368 9.40% 
≥ 5000 3183 90.80% 331 87.70% 3514 90.50% 
Total 3505 100.00% 377 100.00% 3882 100.00% 
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Table 9. Number of Patients by Days of Radiation Therapy Completed by Race 
Days of 
Radiation 
Therapy  
Caucasian 
African-
American Total 
N Pct N Pct N Pct 
< 35  408 11.60% 50 13.20% 458 11.70% 
≥ 35 3101 88.30% 327 86.70% 3428 88.20% 
Total 3509 100.00% 377 100.00% 3886 100.00% 
 
Table 10. Number of Patients by Radiation Dose Intensity and Race  
Radiation Dose 
Intensity  
(rads/day) 
Caucasian 
African-
American Total 
N Pct N Pct N Pct 
< 142.86 644 18.50% 81 21.40% 731 18.80% 
≥ 142.86 2860 81.40% 296 78.50% 3156 81.10% 
Total 3504 100.00% 377 100.00% 3881 100.00% 
 
Table 11 describes the results of the univariate analysis for the outcome radiation dose.  
Race was borderline significant (p=0.06, OR=0.73; 95% CI=0.52-1.01), positive nodes was a 
significant predictor (p=0.04), and protocol was a highly significant (p=<.001) predictor of dose.  
Protocol was the only significant predictor after the forward selection (p= <.0001) (Table 12).  
Because this paper is focusing on comparing African American women and Caucasian women, 
race was added to the model after the forward selection process was applied to other significant 
variables (Table 13).   
Table 14 shows the univariate analysis for the number of days of radiation therapy.  
Protocol was the only significant predictor for the number of days of radiation therapy (p=0.01).  
Therefore after the forward selection, protocol was the only significant predictor (p=0.01) (Table 
15).  Table 16 describes the final multivariate model with race (p=0.51) and protocol (p=0.01). 
Table 17 shows the results of the univariate analysis for radiation dose intensity.  
Protocol was the only highly significant predictors for intensity (p=<.0001).  Table 18 shows the 
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results after the forward selection for intensity.  Protocol was the only highly significant 
predictor of dose intensity (p=<.0001).  Table 19 describes the final multivariate model for 
radiation dose intensity.  Protocol remained significant (p=<.0001).  Race was not a significant 
predictor of intensity (p=.25). 
 
Table 11. Results of Univariate Analysis for Radiation Dose 
Odds Ratio Estimates 
Variables Assessed 
Point 
Estimate 
95% Wald  p-
value 
for 
Chi-
Square  
Confidence Limits 
Race 1 vs. 0 0.728 0.524 1.011 0.0582 
     
Age 1.002 0.991 1.013 0.7544 
     
Pos. Nodes 1 vs. 0 0.629 0.449 0.883 0.0398 
Pos. Nodes 2 vs. 0 0.664 0.45 0.98 
Pos. Nodes 3 vs. 0 0.899 0.489 1.656 
     
Pathologic Tumor Size 1.114 0.996 1.246 0.0579 
     
AC cycle 1 vs. 0 1.361 0.736 2.514 0.3257 
     
Protocol 16 vs. 15 1.581 0.598 4.18 <.0001 
Protocol 18 vs. 15 3.264 1.621 6.575 
Protocol 22 vs. 15 1.063 0.658 1.719 
Protocol 23 vs. 15 0.982 0.6 1.605 
Protocol 25 vs. 15 0.972 0.628 1.504 
Protocol 28 vs. 15 0.592 0.398 0.881 
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Table 12. Results of Forward Selection for Radiation Dose 
Odds Ratio Estimates 
Variables 
Assessed 
Point 
Estimate 
95% Wald p-value 
for 
Chi-
square 
Confidence Limits 
Protocol 16 vs. 15 1.356 0.502 3.658 <.0001 
Protocol 18 vs. 15 3.354 1.585 7.095   
Protocol 22 vs. 15 1.001 0.595 1.686   
Protocol 23 vs. 15 0.925 0.545 1.572   
Protocol 25 vs. 15 0.929 0.577 1.497   
Protocol 28 vs. 15 0.558 0.359 0.866   
 
 
Table 13. Results from Final Multivariate Model for Radiation Dose 
Odds Ratio Estimates 
Variables Assessed 
Point 
Estimate 
95% Wald p-value 
for 
Chi-
square 
Confidence Limits 
Race 1 vs. 0 0.732 0.524 1.021 0.0664 
     
Protocol 16 vs. 15 1.595 0.603 4.218 <.0001 
Protocol 18 vs. 15 3.289 1.632 6.625   
Protocol 22 vs. 15 1.083 0.669 1.751   
Protocol 23 vs. 15 1.024 0.624 1.679   
Protocol 25 vs. 15 0.985 0.636 1.524   
Protocol 28 vs. 15 0.6 0.403 0.893   
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Table 14. Results of Univariate Analysis for Days of Radiation Therapy 
Odds Ratio Estimates 
Variables Assessed 
Point 
Estimate 
95% Wald p-value 
for 
Chi-
Square 
Confidence Limits 
Race 1 vs. 0 0.86 0.628 1.179 0.3497 
     
AGE 1.006 0.996 1.016 0.2487 
     
Pos. Nodes 1 vs. 0 0.815 0.612 1.084 0.3786 
Pos. Nodes 2 vs. 0 0.901 0.642 1.265 
Pos. Nodes 3 vs. 0 0.705 0.439 1.133 
     
Pathologic Tumor Size 1.018 0.925 1.119 0.7209 
     
Last AC cycle 1 vs. 0 0.755 0.378 1.509 0.4262 
     
Protocol 16 vs. 15 1.07 0.479 2.388 0.0124 
Protocol 18 vs. 15 1.339 0.803 2.23 
Protocol 22 vs. 15 0.69 0.45 1.056 
Protocol 23 vs. 15 0.73 0.468 1.139 
Protocol 25 vs. 15 0.803 0.536 1.203 
Protocol 28 vs. 15 0.653 0.447 0.954 
 
 
Table 15.Results of Forward Selection for Days of Radiation Therapy 
Odds Ratio Estimates 
Variables Assessed 
Point 
Estimate 
95% Wald p-value 
for 
Chi-square 
Confidence Limits 
Protocol 16 vs. 15 1.011 0.424 2.413 0.0072 
  
  
  
  
  
Protocol 18 vs. 15 1.191 0.69 2.058 
Protocol 22 vs. 15 0.597 0.373 0.955 
Protocol 23 vs. 15 0.666 0.409 1.086 
Protocol 25 vs. 15 0.722 0.461 1.132 
Protocol 28 vs. 15 0.588 0.384 0.9 
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Table 16. Results from Final Multivariate Model for Radiation Days 
Odds Ratio Estimates 
Variables Assessed 
Point 
Estimate 
95% Wald p-value 
for 
Chi-
square 
Confidence Limits 
Race 1 vs. 0 0.899 0.655 1.234 0.5102 
     
Protocol 16 vs. 15 1.073 0.48 2.394 0.0135 
  
  
  
  
  
Protocol 18 vs. 15 1.342 0.805 2.236 
Protocol 22 vs. 15 0.694 0.453 1.063 
Protocol 23 vs. 15 0.74 0.474 1.157 
Protocol 25 vs. 15 0.806 0.538 1.208 
Protocol 28 vs. 15 0.656 0.449 0.958 
 
 
Table 17.Results of Univariate Analysis for Radiation Dose Intensity 
Odds Ratio Estimates 
Variables Assessed 
Point 
Estimate 
95% Wald  p-value 
for Chi-
Square Confidence Limits 
Race 1 vs. 0 0.831 0.64 1.077 0.1617 
     
Age 1.005 0.996 1.013 0.2617 
     
Pos. Nodes 1 vs. 0 0.744 0.586 0.944 0.1099 
Pos. Nodes 2 vs. 0 0.812 0.614 1.074 
Pos. Nodes 3 vs. 0 0.791 0.524 1.196 
     
Pathologic Tumor Size 1.049 0.968 1.136 0.2442 
     
Last AC cycle 1 vs. 0 0.85 0.494 1.461 0.5557 
     
Protocol 16 vs. 15 1.5 0.711 3.164 <.0001 
Protocol 18 vs. 15 1.671 1.068 2.615 
Protocol 22 vs. 15 0.714 0.497 1.025 
Protocol 23 vs. 15 0.694 0.478 1.008 
Protocol 25 vs. 15 0.763 0.543 1.07 
Protocol 28 vs. 15 0.521 0.38 0.714 
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Table 18. Results of Forward Selection for Radiation Dose Intensity 
Odds Ratio Estimates 
Variables Assessed 
Point 
Estimate 
95% Wald p-value 
for 
Chi-square 
Confidence Limits 
Protocol 16 vs. 15 1.444 0.65 3.21 <.0001 
  
  
  
  
  
Protocol 18 vs. 15 1.588 0.987 2.555 
Protocol 22 vs. 15 0.651 0.439 0.965 
Protocol 23 vs. 15 0.655 0.437 0.982 
Protocol 25 vs. 15 0.716 0.494 1.038 
Protocol 28 vs. 15 0.485 0.342 0.689 
 
Table 19. Results from Final Multivariate Model for Radiation Dose intensity 
Odds Ratio Estimates 
Variables Assessed 
Point 
Estimate 
95% Wald p-value 
for 
Chi-
square 
Confidence Limits 
Race 1 vs. 0 0.857 0.658 1.115 0.2496 
     
Protocol 16 vs. 15 1.506 0.714 3.178 <.0001 
  
  
  
  
  
Protocol 18 vs. 15 1.677 1.072 2.624 
Protocol 22 vs. 15 0.72 0.501 1.034 
Protocol 23 vs. 15 0.708 0.487 1.029 
Protocol 25 vs. 15 0.767 0.546 1.077 
Protocol 28 vs. 15 0.524 0.382 0.719 
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6.0  DISCUSSION 
 
As defined by the NIH,“Cancer health disparities are differences in the incidence, prevalence, 
mortality, and burden of diseases and other adverse health conditions that exist among specific 
population groups in the United States” (NIH 2009).  Examples of this disparity have been noted 
in many studies and apply to the general population.  After examining health disparities, the 
question arose as to whether breast cancer health disparities and radiation treatment disparities 
exist within randomized clinical trials.  
The majority of women in the NSABP clinical trials examined completed the 
recommended number of days [327 AA women (86.7%) and, 3,101 Caucasian women (88.3%)], 
the recommended dose [321 AA women (84.7%) and 183 Caucasian women (90.8%)], thus the 
majority of women completed the recommended dose intensity [327 AA women (86.7%) and 
3,101 Caucasian women (88.3%)].  Even though the majority of women completed the 
recommended radiation therapy African American women received slightly less therapy but not 
at a significant level. 
After adjustment for treatment protocol, race was not a significant predictor of radiation 
dose, duration (days), or intensity in the NSABP clinical trials examined. 
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Breast cancer health disparities, in the general population, were mentioned previously.  
Some factors that may contribute to this disparity are survival difference including lower quality 
of health care when accessible, a higher prevalence of coexisting conditions, differences in 
treatment based on race such as early termination of chemotherapy, SES, sociocultural 
differences, and unequal access to or provision of medical care. Clinical trials, however, are not 
random samples and may not  provide an accurate representation of the total population because 
of the type of environment they provide.  Participants voluntarily join clinical trials for various 
reasons such as compensation, age, gender, or exposure.  There are strict guidelines and 
enrollment criteria which may restrict or prohibit certain individuals from participating.   
Population health disparities  in unequal access to or provision  of medical care and cost may 
have been  eliminated from these clinical trials because of the qualifications and/or restrictions to 
participate.  This may be a possible reason the majority of the women both African American 
and Caucasian completed the recommended radiation therapy.   
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7.0  CONCLUSION 
In conclusion, within the NSABP breast treatment trials examined, the amount of 
radiation therapy provided did not differ significantly between African American and Caucasian 
women.  When using three separate measure of radiation therapy dosing, the majority of women 
completed the recommended radiation therapy and there was no association between race and 
radiation received.   
Public health importance:  Randomized clinical trials provide important evidence for the 
choices of breast cancer treatment.  The success of such trials in providing an environment where 
patients received a standardized treatment would be called into question if there were treatment 
differences by race in those trials. This study did not find evidence of racial disparity in radiation 
therapy in the NSABP breast cancer trials examined. 
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         APPENDIX
 
 EXAMPLE SAS CODE 
 
proc logistic data = logistic descending ; 
class afr_am /  param=ref ref=first;  /*use param=reference because have 
different  
levels of the class variables*/ 
model n_brads = afr_am  /  lackfit rsq outroc=roc clparm=wald clodds=wald 
scale=none  
pprob=0.5 ctable nodummyprint nologscale nocheck aggregate ; /*influence 
iplots ; */ 
/*output out p=hat xbeta=xbeta pred=predict lower=lcl upper=ucl; */ 
output out = mod1 p=y_hat  RESDEV=resdev RESCHI=reschi lower=lcl upper=ucl ;  
/*ods output ParameterEstimates =mod1;*/ 
title 'Model  - Race only. outcome=dose'; 
run; 
proc logistic data = logistic descending outest=betas covout; 
class afr_am pos_nodes last_crs /param=ref ref=first; 
model n_brads = afr_am pos_nodes mpsiz age last_crs/lackfit rsq outroc=roc1  
clparm=wald clodds=wald scale=none pprob=0.5 ctable nodummyprint nologscale 
nocheck  
aggregate SELECTION=F SLENTRY=0.05  DETAILS/*influence iplots */; 
/*out p=hat xbeta=xbeta pred=predict lower=lcl upper=ucl; */ 
output out = mod1L p=y_hat RESDEV=resdev RESCHI=reschi lower=lcl upper=ucl; 
/*ods output ParameterEstimates =mod1l;*/ 
title 'Model  - FOWARD SELECTION ALL. outcome=dose'; 
run;. 
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this thesis these terms are synonymous 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
